Hemodynamic, hormone, and urinary effects of adrenomedullin infusion in essential hypertension.
We examined the effects of the vasodilator peptide adrenomedullin (AM) infused intravenously into subjects with essential hypertension. Eight men 39 to 58 years old with uncomplicated hypertension (147/96+/-5/3 mm Hg at baseline) were studied in a placebo-controlled, crossover design. Each subject received intravenous AM in a low and a high dose (2.9 and 5.8 pmol. kg(-1). min(-1) for 2 hours each) or vehicle-control (Hemaccel) infusion in a random order on day 4 of a controlled metabolic diet (80 mmol/d Na(+), 100 mmol/d K(+)). Plasma AM reached pathophysiological levels during infusion (18+/-4 pmol/L in low dose, 34+/-9 pmol/L in high dose) with a concurrent rise in plasma cAMP (+8.4+/-1.2 pmol/L, P:<0. 05 compared with control). Compared with control, high-dose AM increased peak heart rate (+17.8+/-2.3 bpm, P<0.01), lowered systolic (-24.6+/-0.9 mm Hg; P<0.01) and diastolic (-21.9+/-1.4 mm Hg; P<0.01) blood pressure, and increased cardiac output (+1.0+/-0. 1 L/min in low dose, +2.9+/-0.2 L/min in high dose; P<0.01 for both). Despite a rise in plasma renin activity during high dose (P<0.05), aldosterone levels did not alter. Plasma norepinephrine levels increased 1295+/-222 pmol/L (P<0.001) and epinephrine increased 74+/-15 pmol/L (P<0.05) with high-dose AM compared with control. AM had no significant effect on urine volume and sodium excretion. In subjects with essential hypertension, the intravenous infusion of AM to achieve pathophysiological levels produced significant falls in arterial pressure, increased heart rate and cardiac output, and stimulated the sympathetic system and renin release without concurrent increase in aldosterone. Urinary parameters were unaltered. Although AM has potent hemodynamic and neurohumoral effects in subjects with essential hypertension, the threshold for urinary actions is set higher.
Troughton
R W
RW
Christchurch Cardioendocrine Research Group, Christchurch Hospital and Christchurch School of Medicine, Christchurch, New Zealand. richard.troughton@chmeds.ac.nz
Lewis
L K
LK
Yandle
T G
TG
Richards
A M
AM
Nicholls
M G
MG
D053607:Adrenomedullin; D000328:Adult; D000450:Aldosterone / Q000097:blood / Q000652:urine; D009320:Atrial Natriuretic Factor / Q000097:blood; D003404:Creatinine / Q000652:urine; D018592:Cross-Over Studies; D000242:Cyclic AMP / Q000097:blood / Q000652:urine; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009638:Norepinephrine / Q000097:blood; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D010455:Peptides; D011188:Potassium / Q000652:urine; D017419:Potassium, Dietary; D011388:Prolactin / Q000097:blood; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D012982:Sodium, Dietary
D010446:Peptide Fragments; D010455:Peptides; D017419:Potassium, Dietary; D012982:Sodium, Dietary; D020097:Natriuretic Peptide, Brain; D053607:Adrenomedullin; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D011388:Prolactin; D012964:Sodium; D003404:Creatinine; D000242:Cyclic AMP; D012083:Renin; D011188:Potassium; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine